文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

每周一次司美格鲁肽用于超重或肥胖成人

Once-Weekly Semaglutide in Adults with Overweight or Obesity.
PubMed 文献 · N Engl J Med · 2021-02-10

这项双盲试验纳入1961例无糖尿病的超重或肥胖成人,按2:1随机接受每周皮下司美格鲁肽2.4 mg或安慰剂加生活方式干预68周。司美格鲁肽组体重平均下降14.9%,安慰剂组下降2.4%,治疗差异为-12.4个百分点(95%CI -13.4至-11.5;P<0.001)。司美格鲁肽组更多受试者达到≥5%、≥10%和≥15%的体重下降,胃肠不良事件常见但多为短暂轻中度。

要点

  • 每周一次司美格鲁肽2.4 mg加生活方式干预68周使体重平均下降14.9%,安慰剂组为2.4%。
  • 司美格鲁肽组86.4%受试者体重下降≥5%,安慰剂组为31.5%。
  • 恶心和腹泻是最常见不良事件,多短暂轻中度;因胃肠事件停药者司美格鲁肽组4.5%,安慰剂组0.8%。

核心结论

  • 在超重或肥胖成人中,每周一次司美格鲁肽2.4 mg加生活方式干预与持续且有临床意义的体重下降相关。

研究设计与样本

  • 双盲试验纳入1961例无糖尿病的超重或肥胖成人,按2:1随机接受68周每周皮下司美格鲁肽2.4 mg或安慰剂加生活方式干预。

主要发现

  • 体重从基线至第68周平均变化司美格鲁肽组为-14.9%,安慰剂组为-2.4%,估计治疗差异-12.4个百分点(95%CI -13.4至-11.5;P<0.001)。
  • 司美格鲁肽组1047例(86.4%)体重下降≥5%,安慰剂组182例(31.5%);838例(69.1%)vs. 69例(12.0%)下降≥10%;612例(50.5%)vs. 28例(4.9%)下降≥15%(三项比较P<0.001)。
  • 体重从基线至第68周变化司美格鲁肽组为-15.3 kg,安慰剂组为-2.6 kg,估计治疗差异-12.7 kg(95%CI -13.7至-11.7)。
  • 司美格鲁肽组心脏代谢危险因素改善更大,受试者报告的躯体功能从基线增加更多。
  • 恶心和腹泻是司美格鲁肽最常见不良事件,通常短暂、轻中度并随时间消退;因胃肠事件停药司美格鲁肽组59例(4.5%),安慰剂组5例(0.8%)。

临床怎么用

  • 对于无糖尿病的超重或肥胖成人,可考虑每周一次司美格鲁肽2.4 mg联合生活方式干预以辅助减重。
  • 用药期间应关注胃肠道不良事件,多数短暂轻中度,但部分患者可能因胃肠事件停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed. METHODS: In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. The coprimary end points were the percentage change in body weight and weight reduction of at least 5%. The primary estimand (a precise description of the treatment effect reflecting the objective of the clinical trial) assessed effects regardless of treatment discontinuation or rescue interventions. RESULTS: The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001). More participants in the semaglutide group than in the placebo group achieved weight reductions of 5% or more (1047 participants [86.4%] vs. 182 [31.5%]), 10% or more (838 [69.1%] vs. 69 [12.0%]), and 15% or more (612 [50.5%] vs. 28 [4.9%]) at week 68 (P<0.001 for all three comparisons of odds). The change in body weight from baseline to week 68 was -15.3 kg in the semaglutide group as compared with -2.6 kg in the placebo group (estimated treatment difference, -12.7 kg; 95% CI, -13.7 to -11.7). Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo. Nausea and diarrhea were the most common adverse events with semaglutide; they were typically transient and mild-to-moderate in severity and subsided with time. More participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]). CONCLUSIONS: In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185. doi:10.1056/NEJMoa2032183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。